title: Charting a path toward combination therapy for Alzheimer's disease.
abstract: It is acknowledged that progress in combined therapeutic approaches for Alzheimer's disease (AD) will require an unprecedented level of collaboration. At a meeting co-hosted by the Accelerate Cure/Treatments for Alzheimer's Disease Coalition and the Critical Path Institute, investigators from industry, academia and regulatory agencies agreed on the need for combinatorial approaches to treating AD. The need for advancing multiple targets includes recognition for novel adaptive trial designs that incorporate existing and new biomarkers to evaluate drug effects independently and in combination. A combination trial now being planned may test drugs targeting different pathogenic pathways or multiple targets along a common pathway. Collaborations and consortia-based strategies are pivotal for success and a regulatory framework is recommended for success.
authors.affiliation: CAMD, Critical Path Institute, Tucson, AZ 85718, USA.
authors.forename: Diane
authors.initials: D
authors.lastname: Stephenson
authors.forename: Dan
authors.initials: D
authors.lastname: Perry
authors.forename: Cynthia
authors.initials: C
authors.lastname: Bens
authors.forename: Lisa J
authors.initials: LJ
authors.lastname: Bain
authors.forename: Donald
authors.initials: D
authors.lastname: Berry
authors.forename: Michael
authors.initials: M
authors.lastname: Krams
authors.forename: Reisa
authors.initials: R
authors.lastname: Sperling
authors.forename: David
authors.initials: D
authors.lastname: Dilts
authors.forename: Johan
authors.initials: J
authors.lastname: Luthman
authors.forename: Debra
authors.initials: D
authors.lastname: Hanna
authors.forename: John
authors.initials: J
authors.lastname: McKew
authors.forename: Robert
authors.initials: R
authors.lastname: Temple
authors.forename: F Owen
authors.initials: FO
authors.lastname: Fields
authors.forename: Stephen
authors.initials: S
authors.lastname: Salloway
authors.forename: Russell
authors.initials: R
authors.lastname: Katz
mesh_terms: D000047:Academies and Institutes; D000544:Alzheimer Disease / Q000628:therapy*; D000818:Animals; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D004335:Drug and Narcotic Control / Q000379:methods / Q000639:trends; D006801:Humans; D055818:Public-Private Sector Partnerships / Q000639:trends
chemical_list: D014150:Antipsychotic Agents
keywords: Alzheimer’s disease; co-development; collaboration; combination therapy; novel therapy